{
  "claims": [
    {
      "metric_type": "revenue",
      "qualifiers": [],
      "confidence": 1,
      "comparison_period": "Q1 2024",
      "quote_start_char": 2749,
      "claimed_value_raw": "4.2%",
      "is_approximate": false,
      "speaker_role": "ceo",
      "claimed_value": 4.2,
      "quote_end_char": 2844,
      "scale": null,
      "claim_id": "claim_001",
      "unit": "percent",
      "claim_type": "yoy_growth",
      "metric_context": "Total",
      "quote_text": "In the first quarter, we delivered strong operational sales growth of 4.2% across our business.",
      "period": "Q1 2025",
      "gaap_classification": "non_gaap",
      "speaker": "Joaquin Duato"
    },
    {
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "period": "Q1 2025",
      "quote_text": "In innovative medicine, we delivered 4.2% operational sales growth despite an approximate 810 basis points headwind from STELARA",
      "metric_context": "Innovative Medicine",
      "claim_type": "yoy_growth",
      "claim_id": "claim_002",
      "unit": "percent",
      "scale": null,
      "quote_end_char": 4026,
      "speaker_role": "ceo",
      "claimed_value": 4.2,
      "is_approximate": false,
      "claimed_value_raw": "4.2%",
      "comparison_period": "Q1 2024",
      "quote_start_char": 3898,
      "confidence": 1,
      "qualifiers": [],
      "metric_type": "revenue"
    },
    {
      "quote_end_char": 4174,
      "claimed_value": 3,
      "speaker_role": "ceo",
      "is_approximate": false,
      "claimed_value_raw": "$3 billion",
      "confidence": 1,
      "comparison_period": null,
      "quote_start_char": 4074,
      "qualifiers": [
        "above"
      ],
      "metric_type": "revenue",
      "speaker": "Joaquin Duato",
      "period": "Q1 2025",
      "quote_text": "With our third consecutive quarter of sales above $3 billion, DARZALEX continues to set the standard",
      "gaap_classification": "gaap",
      "metric_context": "DARZALEX",
      "claim_type": "absolute",
      "unit": "dollars",
      "claim_id": "claim_003",
      "scale": "billions"
    },
    {
      "qualifiers": [
        "over"
      ],
      "confidence": 1,
      "comparison_period": "Q1 2024",
      "quote_start_char": 4195,
      "metric_type": "revenue",
      "speaker_role": "ceo",
      "claimed_value": 20,
      "quote_end_char": 4235,
      "claimed_value_raw": "20%",
      "is_approximate": false,
      "claim_type": "yoy_growth",
      "scale": null,
      "claim_id": "claim_004",
      "unit": "percent",
      "speaker": "Joaquin Duato",
      "metric_context": "DARZALEX",
      "quote_text": "with another quarter of over 20% growth.",
      "period": "Q1 2025",
      "gaap_classification": "gaap"
    },
    {
      "claim_type": "yoy_growth",
      "scale": null,
      "unit": "percent",
      "claim_id": "claim_005",
      "speaker": "Joaquin Duato",
      "metric_context": "Tremfya",
      "gaap_classification": "non_gaap",
      "period": "Q1 2025",
      "quote_text": "launch in ulcerative colitis helping accelerate operational sales growth to 20%.",
      "qualifiers": [],
      "comparison_period": "Q1 2024",
      "quote_start_char": 5419,
      "confidence": 1,
      "metric_type": "revenue",
      "claimed_value": 20,
      "speaker_role": "ceo",
      "quote_end_char": 5499,
      "claimed_value_raw": "20%",
      "is_approximate": false
    },
    {
      "claim_type": "yoy_growth",
      "claim_id": "claim_006",
      "unit": "percent",
      "scale": null,
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "quote_text": "Turning to MedTech, in Q1, we delivered 4.1% operational sales growth with strong performance",
      "period": "Q1 2025",
      "metric_context": "MedTech",
      "comparison_period": "Q1 2024",
      "quote_start_char": 5688,
      "confidence": 1,
      "qualifiers": [],
      "metric_type": "revenue",
      "quote_end_char": 5781,
      "speaker_role": "ceo",
      "claimed_value": 4.1,
      "is_approximate": false,
      "claimed_value_raw": "4.1%"
    },
    {
      "metric_type": "revenue",
      "confidence": 1,
      "comparison_period": null,
      "quote_start_char": 14174,
      "qualifiers": [],
      "is_approximate": false,
      "claimed_value_raw": "$21.9 billion",
      "quote_end_char": 14245,
      "speaker_role": "management",
      "claimed_value": 21.9,
      "claim_id": "claim_007",
      "unit": "dollars",
      "scale": "billions",
      "claim_type": "absolute",
      "period": "Q1 2025",
      "quote_text": "Starting with Q1 2025 sales results, worldwide sales were $21.9 billion",
      "gaap_classification": "gaap",
      "metric_context": "Total",
      "speaker": "Jessica Moore"
    },
    {
      "claim_id": "claim_008",
      "unit": "dollars",
      "scale": "billions",
      "claim_type": "absolute",
      "gaap_classification": "gaap",
      "quote_text": "Turning now to earnings, for the quarter, net earnings were $11 billion",
      "period": "Q1 2025",
      "metric_context": "Total",
      "speaker": "Jessica Moore",
      "metric_type": "net_income",
      "comparison_period": null,
      "quote_start_char": 14462,
      "confidence": 1,
      "qualifiers": [],
      "is_approximate": false,
      "claimed_value_raw": "$11 billion",
      "quote_end_char": 14533,
      "claimed_value": 11,
      "speaker_role": "management"
    },
    {
      "confidence": 1,
      "comparison_period": null,
      "quote_start_char": 14538,
      "qualifiers": [],
      "metric_type": "eps_diluted",
      "quote_end_char": 14628,
      "claimed_value": 4.54,
      "speaker_role": "management",
      "is_approximate": false,
      "claimed_value_raw": "$4.54",
      "claim_type": "absolute",
      "unit": "per_share",
      "claim_id": "claim_009",
      "scale": null,
      "speaker": "Jessica Moore",
      "period": "Q1 2025",
      "quote_text": "diluted earnings per share was $4.54 versus diluted earnings per share of $1.34 a year ago",
      "gaap_classification": "gaap",
      "metric_context": "Total"
    },
    {
      "claim_type": "absolute",
      "claim_id": "claim_010",
      "unit": "dollars",
      "scale": "billions",
      "speaker": "Jessica Moore",
      "gaap_classification": "non_gaap",
      "quote_text": "Excluding after-tax intangible and special items for both periods, adjusted net earnings for the quarter were $6.7 billion",
      "period": "Q1 2025",
      "metric_context": "Total",
      "comparison_period": null,
      "quote_start_char": 14718,
      "confidence": 1,
      "qualifiers": [],
      "metric_type": "net_income",
      "quote_end_char": 14840,
      "claimed_value": 6.7,
      "speaker_role": "management",
      "is_approximate": false,
      "claimed_value_raw": "$6.7 billion"
    },
    {
      "claim_type": "absolute",
      "scale": null,
      "claim_id": "claim_011",
      "unit": "per_share",
      "speaker": "Jessica Moore",
      "metric_context": "Total",
      "gaap_classification": "non_gaap",
      "quote_text": "adjusted diluted earnings per share was $2.77, representing increases of 1.9% and 2.2% respectively compared to the first quarter of 2024.",
      "period": "Q1 2025",
      "qualifiers": [],
      "quote_start_char": 14845,
      "comparison_period": null,
      "confidence": 1,
      "metric_type": "eps_diluted",
      "claimed_value": 2.77,
      "speaker_role": "management",
      "quote_end_char": 14983,
      "claimed_value_raw": "$2.77",
      "is_approximate": false
    },
    {
      "qualifiers": [],
      "confidence": 1,
      "comparison_period": null,
      "quote_start_char": 15186,
      "metric_type": "revenue",
      "claimed_value": 13.9,
      "speaker_role": "management",
      "quote_end_char": 15269,
      "claimed_value_raw": "$13.9 billion",
      "is_approximate": false,
      "claim_type": "absolute",
      "scale": "billions",
      "claim_id": "claim_012",
      "unit": "dollars",
      "speaker": "Jessica Moore",
      "metric_context": "Innovative Medicine",
      "quote_text": "Beginning with innovative medicine, worldwide sales of $13.9 billion increased 4.2%",
      "period": "Q1 2025",
      "gaap_classification": "gaap"
    },
    {
      "metric_type": "revenue",
      "confidence": 1,
      "comparison_period": "Q1 2024",
      "quote_start_char": 15390,
      "qualifiers": [],
      "is_approximate": false,
      "claimed_value_raw": "22.5%",
      "quote_end_char": 15435,
      "speaker_role": "management",
      "claimed_value": 22.5,
      "claim_id": "claim_013",
      "unit": "percent",
      "scale": null,
      "claim_type": "yoy_growth",
      "period": "Q1 2025",
      "quote_text": "Starting with oncology, SARS growth was 22.5%",
      "gaap_classification": "gaap",
      "metric_context": "Oncology",
      "speaker": "Jessica Moore"
    },
    {
      "claim_id": "claim_014",
      "unit": "dollars",
      "scale": "millions",
      "claim_type": "absolute",
      "gaap_classification": "gaap",
      "period": "Q1 2025",
      "quote_text": "Pervixi achieved sales of $369 million and growth of over 100%",
      "metric_context": "CARVYKTI",
      "speaker": "Jessica Moore",
      "metric_type": "revenue",
      "comparison_period": null,
      "quote_start_char": 15618,
      "confidence": 1,
      "qualifiers": [],
      "is_approximate": false,
      "claimed_value_raw": "$369 million",
      "quote_end_char": 15680,
      "speaker_role": "management",
      "claimed_value": 369
    },
    {
      "scale": null,
      "unit": "percent",
      "claim_id": "claim_015",
      "claim_type": "yoy_growth",
      "metric_context": "STELARA",
      "gaap_classification": "gaap",
      "quote_text": "STELARA declined 32.3%",
      "period": "Q1 2025",
      "speaker": "Jessica Moore",
      "metric_type": "revenue",
      "qualifiers": [],
      "quote_start_char": 16495,
      "comparison_period": "Q1 2024",
      "confidence": 1,
      "claimed_value_raw": "32.3%",
      "is_approximate": false,
      "claimed_value": 32.3,
      "speaker_role": "management",
      "quote_end_char": 16517
    },
    {
      "scale": "billions",
      "claim_id": "claim_016",
      "unit": "dollars",
      "claim_type": "absolute",
      "metric_context": "MedTech",
      "gaap_classification": "gaap",
      "period": "Q1 2025",
      "quote_text": "Turning now to MedTech. Worldwide sales of $8 billion increased 4.1%",
      "speaker": "Jessica Moore",
      "metric_type": "revenue",
      "qualifiers": [],
      "comparison_period": null,
      "quote_start_char": null,
      "confidence": 1,
      "claimed_value_raw": "$8 billion",
      "is_approximate": false,
      "claimed_value": 8,
      "speaker_role": "management",
      "quote_end_char": null
    },
    {
      "metric_type": "free_cash_flow",
      "qualifiers": [
        "approximately"
      ],
      "confidence": 1,
      "quote_start_char": 24833,
      "comparison_period": null,
      "claimed_value_raw": "$3.4 billion",
      "is_approximate": true,
      "claimed_value": 3.4,
      "speaker_role": "cfo",
      "quote_end_char": 24917,
      "scale": "billions",
      "unit": "dollars",
      "claim_id": "claim_017",
      "claim_type": "absolute",
      "metric_context": "Total",
      "period": "Q1 2025",
      "quote_text": "pleased with free cash flow generation in the quarter of approximately $3.4 billion.",
      "gaap_classification": "unknown",
      "speaker": "Joe Wolk"
    },
    {
      "claim_type": "absolute",
      "scale": "billions",
      "unit": "dollars",
      "claim_id": "claim_018",
      "speaker": "Joe Wolk",
      "metric_context": "Total",
      "period": "Q1 2025",
      "quote_text": "during the first quarter, we invested more than $3 billion in research and development, approximately 15% of sales.",
      "gaap_classification": "gaap",
      "qualifiers": [
        "more than"
      ],
      "confidence": 1,
      "quote_start_char": 25431,
      "comparison_period": null,
      "metric_type": "research_and_development",
      "speaker_role": "cfo",
      "claimed_value": 3,
      "quote_end_char": 25546,
      "claimed_value_raw": "$3 billion",
      "is_approximate": false
    },
    {
      "metric_type": "revenue",
      "qualifiers": [],
      "quote_start_char": 26640,
      "comparison_period": "FY 2024",
      "confidence": 1,
      "claimed_value_raw": "3.8%",
      "is_approximate": false,
      "speaker_role": "cfo",
      "claimed_value": 3.8,
      "quote_end_char": 26771,
      "scale": null,
      "claim_id": "claim_019",
      "unit": "percent",
      "claim_type": "guidance",
      "metric_context": "Total",
      "gaap_classification": "non_gaap",
      "period": "FY 2025",
      "quote_text": "we now expect operational sales growth for the full year to be in the range of 3.3% to 4.3% with a midpoint of $92 billion or 3.8%.",
      "speaker": "Joe Wolk"
    },
    {
      "unit": "per_share",
      "claim_id": "claim_020",
      "scale": null,
      "claim_type": "guidance",
      "period": "FY 2025",
      "quote_text": "based on what is in place today, we are pleased to be able to maintain our adjusted reported earnings per share guidance of 6.2% at the midpoint for a range of $10.50 to $10.70, partially aided by the reduced FX impact.",
      "gaap_classification": "non_gaap",
      "metric_context": "Total",
      "speaker": "Joe Wolk",
      "metric_type": "eps_diluted",
      "confidence": 1,
      "comparison_period": null,
      "quote_start_char": 28089,
      "qualifiers": [],
      "is_approximate": false,
      "claimed_value_raw": "$10.60",
      "quote_end_char": 28308,
      "claimed_value": 10.6,
      "speaker_role": "cfo"
    }
  ],
  "total_claims_found": 20,
  "transcript_summary": "Johnson & Johnson reported Q1 2025 results with 4.2% operational sales growth and maintained its full-year EPS guidance despite headwinds from biosimilar competition and acquisition dilution.",
  "ticker": "JNJ",
  "year": 2025,
  "quarter": 1,
  "extracted_at": "2026-02-13T17:38:06.137583"
}